Skip to content
November 15, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Kanker Payudara

Kanker Payudara

Primary Menu
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Watch
  • Home
  • Medical Research and Clinical Trials
  • AI Revolutionizes Breast Cancer Detection: UCLA Study Unveils Potential for Earlier Diagnosis of Elusive Interval Cancers
  • Medical Research and Clinical Trials

AI Revolutionizes Breast Cancer Detection: UCLA Study Unveils Potential for Earlier Diagnosis of Elusive Interval Cancers

Nila Kartika Wati November 15, 2026 21 minutes read
ai-revolutionizes-breast-cancer-detection-ucla-study-unveils-potential-for-earlier-diagnosis-of-elusive-interval-cancers

LOS ANGELES, CA – A groundbreaking study spearheaded by investigators at the UCLA Health Jonsson Comprehensive Cancer Center suggests that artificial intelligence (AI) could herald a new era in breast cancer screening, significantly improving the early detection of interval breast cancers – those insidious malignancies that emerge between routine mammography appointments. The research, published in the prestigious Journal of the National Cancer Institute, highlights AI’s remarkable ability to identify subtle, often overlooked, signs of these cancers at the initial screening stage, potentially leading to a substantial reduction in their incidence, earlier and less aggressive treatment, and ultimately, improved patient outcomes.

Interval breast cancers pose a significant challenge in oncology. Unlike screen-detected cancers, which are found during scheduled examinations, interval cancers manifest rapidly or are missed during initial readings, often presenting at a more advanced stage, making them harder to treat and associated with a less favorable prognosis. The UCLA study posits that by integrating AI into the diagnostic workflow, the number of these difficult-to-detect cancers could be reduced by an estimated 30%, a figure that could translate into countless lives saved and vastly improved quality of life for patients.

"This finding is important because these interval cancer types could be caught earlier when the cancer is easier to treat," stated Dr. Tiffany Yu, assistant professor of Radiology at the David Geffen School of Medicine at UCLA and the study’s first author. "For patients, catching cancer early can make all the difference. It can lead to less aggressive treatment and improve the chances of a better outcome."

While AI’s application in medical imaging is a rapidly evolving field, this study is particularly notable as it is among the first to rigorously explore its utility in detecting interval breast cancers within the unique context of U.S. screening practices. Previous research, predominantly conducted in Europe, often focused on different screening modalities and schedules, underscoring the critical need for U.S.-specific data to validate and advance this promising technology.


Main Facts: A New Frontier in Early Detection

The core revelation from the UCLA Health Jonsson Comprehensive Cancer Center study is the compelling evidence that AI holds immense promise in overcoming one of the persistent challenges in breast cancer screening: the detection of interval cancers. These cancers, by their very definition, are diagnostically elusive, either growing aggressively in the period between screenings or presenting with such subtle radiographic indicators that they evade human detection during initial review.

The study’s primary finding asserts that AI, when applied to initial screening mammograms, demonstrated a significant capacity to identify "mammographically-visible" interval cancers earlier. These are not cancers that are truly invisible to imaging, but rather those whose signs are present on the mammogram but are either missed by radiologists due to human error, or are so faint and ambiguous that they fall below the threshold of reliable human perception. The AI’s strength lies in its ability to discern these minute patterns, offering a powerful "second set of eyes" to augment the diagnostic process.

The estimated 30% reduction in interval breast cancers is a pivotal statistic. This is not merely an incremental improvement but a substantial leap forward that could fundamentally alter the landscape of breast cancer care. For patients, this translates directly into a higher probability of early-stage diagnosis, which is universally correlated with less invasive treatment options, higher survival rates, and a significantly improved prognosis. Instead of facing aggressive chemotherapy, extensive surgery, or radiation for advanced disease, patients could potentially undergo more localized, targeted interventions, preserving their health and quality of life.

Dr. Tiffany Yu’s emphasis on the patient-centric benefits underscores the profound impact of these findings. The difference between an early diagnosis and a later one can indeed be "all the difference" – a shift from a potentially life-threatening battle to a manageable condition with a high likelihood of successful remission. This perspective highlights the urgency and importance of further research and clinical implementation of such AI tools.

However, the study also responsibly acknowledges the current limitations of AI. As Dr. Hannah Milch, assistant professor of Radiology at the David Geffen School of Medicine and senior author of the study, noted, "While we had some exciting results, we also uncovered a lot of AI inaccuracy and issues that need to be further explored in real-world settings." This balanced view is crucial for the responsible integration of AI into clinical practice, ensuring that its benefits are maximized while its current imperfections are understood and addressed through continued development and rigorous testing. The goal, as the researchers articulate, is not to replace human expertise but to enhance it, empowering radiologists with more sophisticated tools to provide the best possible care.


Chronology: From Diagnostic Challenge to AI Innovation

The journey to the UCLA study’s findings is rooted in a long-standing diagnostic challenge in breast cancer screening and the relatively recent advent of sophisticated AI technologies capable of addressing it.

The Enduring Challenge of Interval Cancers:
For decades, medical professionals have grappled with interval breast cancers. Despite the widespread adoption of regular mammography screening, a subset of cancers inevitably emerges between scheduled appointments. These cancers are particularly concerning because they are often more aggressive, faster-growing, and tend to present at a later stage compared to screen-detected cancers. Their insidious nature means that by the time they are clinically apparent (e.g., a palpable lump), they may have progressed significantly, limiting treatment options and worsening prognosis. The very subtle nature of their early signs on mammograms, often described as faint or ambiguous, makes them extremely challenging for even highly experienced radiologists to consistently identify. Factors such as variations in breast density, the sheer volume of images to review, and the inherent limitations of human visual perception and fatigue contribute to these missed detections.

The Rise of AI in Medical Imaging:
In recent years, advancements in computing power, machine learning algorithms, and access to vast datasets have propelled artificial intelligence to the forefront of medical innovation. AI, particularly deep learning, has shown remarkable capabilities in pattern recognition, making it a natural fit for image analysis in radiology. From detecting subtle lung nodules to identifying diabetic retinopathy, AI has begun to demonstrate its potential as a powerful diagnostic aid. In mammography, early AI applications focused on improving lesion detection, breast density assessment, and risk stratification. These foundational developments paved the way for more specialized applications, such as the detection of interval cancers.

Divergent Screening Practices: The U.S. vs. Europe:
Before the UCLA study, much of the research into AI’s role in interval cancer detection originated from Europe. However, crucial differences exist between U.S. and European breast cancer screening programs. In the United States, digital breast tomosynthesis (DBT), often referred to as 3D mammography, has become the predominant screening modality. DBT acquires multiple images from different angles, creating a 3D reconstruction of the breast, which helps reduce tissue overlap and improves cancer detection, especially in dense breasts. Furthermore, U.S. guidelines typically recommend annual screening for women over 40.

In contrast, many European screening programs historically relied on digital mammography (DM), or 2D mammography, which provides a single, flattened image of the breast. Screening intervals in Europe are often longer, typically every two to three years. These differences in technology and frequency mean that findings from European AI studies, while valuable, may not be directly transferable to the U.S. context. The unique characteristics of DBT imaging and annual screening presented a specific research gap that the UCLA team aimed to address.

The Genesis of the UCLA Study:
Recognizing this critical gap, investigators at the UCLA Health Jonsson Comprehensive Cancer Center initiated their study. The primary motivation was to rigorously assess if AI could provide similar or even enhanced benefits in the U.S. screening environment, specifically targeting the detection of interval cancers under the prevailing use of DBT and annual screening schedules. The study sought to answer whether AI could identify cancers that were "mammographically-visible" but missed by human radiologists in the American context, thus complementing existing screening efforts.

Methodological Rigor: A Retrospective Deep Dive:
The UCLA team embarked on a comprehensive retrospective study, analyzing a vast dataset of nearly 185,000 past mammograms performed between 2010 and 2019. This extensive period allowed for the inclusion of both DM and, significantly, DBT images, reflecting the transition in screening technology over the decade. From this massive pool of data, the researchers meticulously identified 148 cases where a woman was subsequently diagnosed with interval breast cancer. These 148 cases formed the core of their in-depth analysis.

Classifying the Unseen:
To understand why these cancers were not detected during initial screening, a panel of experienced radiologists meticulously re-reviewed each of the 148 interval cancer cases. They adapted a well-established European classification system to categorize these cancers, providing a nuanced understanding of the reasons for missed detection:

  • Missed reading error: The cancer was visible on the mammogram, but the radiologist simply overlooked it. This highlights the human element of fatigue, distraction, or perceptual error.
  • Minimal signs-actionable: Subtle signs of cancer were present on the mammogram, and a highly attentive or second review could have reasonably led to further investigation or action.
  • Minimal signs-non-actionable: Extremely subtle signs were present, arguably below the reliable level of human detection, making it very difficult for a radiologist to confidently identify them as suspicious.
  • True interval cancer: The breast appeared clear at the time of screening, and the cancer genuinely developed and became detectable in the period after the screening. These are the "true" de novo cancers that AI would likely not have caught.
  • Occult: The cancer was truly invisible on the mammogram, regardless of human or AI review. These cancers are often identified by other means, such as ultrasound or MRI, or by clinical symptoms.
  • Missed due to a technical error: Issues with image quality, positioning, or equipment malfunction led to the missed detection.

This detailed classification was crucial for understanding where AI could potentially intervene most effectively. The "missed reading error," "minimal signs-actionable," and "minimal signs-non-actionable" categories represented the prime targets for AI assistance, as these were the cancers whose signs were physically present on the mammogram.

AI’s Diagnostic Test Drive:
With the interval cancer cases meticulously classified, the researchers then applied a commercially available AI software called Transpara to the initial screening mammograms (those taken before the cancer diagnosis). Transpara is designed to assist radiologists by identifying suspicious areas on mammograms and assigning a risk score. The tool generates a score from 1 to 10 for cancer risk, with a score of 8 or higher flagging the mammogram as potentially concerning and warranting closer human scrutiny. The objective was to determine if the AI could detect those subtle signs that were missed by radiologists during the initial screenings, or at least flag them as suspicious for further review. This comprehensive and meticulous chronological approach allowed the UCLA team to systematically evaluate AI’s potential and limitations in a real-world clinical context.


Supporting Data: Unpacking AI’s Performance and Limitations

The UCLA study’s robust methodology yielded critical data points that illuminate both the significant promise and the current frontiers of AI in breast cancer detection.

The 30% Reduction Potential:
The headline figure – an estimated 30% reduction in interval breast cancers – stems directly from the AI’s performance on the "mammographically-visible" categories. While the study is retrospective and cannot definitively prove this reduction in a real-world prospective setting, the data strongly suggests that AI could have flagged a substantial proportion of cancers categorized as "missed reading error," "minimal signs-actionable," and even some "minimal signs-non-actionable." These are the cancers that, with the AI’s assistance, could have been caught earlier. This 30% represents a significant portion of the interval cancer burden that is currently missed, offering a tangible target for improvement in screening efficacy. For context, even a modest percentage reduction in cancer incidence can translate to thousands of lives affected annually.

Targeting Missed Cancers:
The study implies that the AI tool was particularly effective in identifying those subtle lesions that human radiologists either missed entirely or deemed too ambiguous to warrant further investigation. While specific percentages for each "mammographically-visible" category are not explicitly detailed in the provided text for AI detection rates, the overall finding of a 30% potential reduction strongly indicates the AI’s proficiency in these areas. For instance, in cases classified as "missed reading error," where the cancer was visibly present but overlooked, an AI system trained on vast datasets of cancer morphology would likely have a high detection rate. Similarly, for "minimal signs-actionable" cases, where subtle clues were present, AI’s pattern recognition capabilities could reliably highlight these areas for human review. Even in "minimal signs-non-actionable" cases, where signs were borderline, AI might err on the side of caution, flagging areas that a human eye might dismiss as benign or too ambiguous, thereby increasing the chance of early intervention.

The Occult Cancer Paradox: Promise and Precision Challenges:
One of the most intriguing and nuanced findings of the study concerns occult cancers – those truly invisible on mammography. Surprisingly, the AI tool still flagged 69% of the initial screening mammograms that later proved to have occult cancers, assigning them a risk score of 8 or higher. This suggests that the AI might be detecting extremely subtle, perhaps even sub-visual, textural or architectural changes that are predictive of future cancer development, even if the cancer itself isn’t directly visible. This opens up a fascinating avenue for future research into AI’s ability to predict risk beyond current visual capabilities.

However, the study also revealed a critical limitation in this specific context: when the AI flagged these occult cancer cases, it only accurately pinpointed the actual cancer location in 22% of the instances. This discrepancy highlights a key challenge for AI in its current form: while it might be good at identifying a mammogram as suspicious or high-risk (the 69% flagging rate), its ability to precisely localize the exact cancerous lesion within that mammogram, especially when it’s not visually obvious, is still imperfect (the 22% localization rate).

Implications of AI’s Precision Issues:
This disparity in flagging versus localization for occult cancers has significant practical implications. If AI flags a mammogram as suspicious but cannot accurately indicate where the concern lies, it could lead to increased patient callbacks for further imaging (e.g., ultrasound, MRI) and biopsies. While these may ultimately lead to a diagnosis, an excess of non-specific flags could burden healthcare systems, increase patient anxiety, and potentially lead to unnecessary invasive procedures. This finding underscores the need for AI algorithms to improve not just in detection, but also in precise spatial localization, particularly for the most challenging cases.

Comparison to Human Performance (Implicit):
While the study did not conduct a direct head-to-head comparison of AI versus individual human radiologists on the same dataset in a live setting, the very premise of targeting "missed reading errors" and "minimal signs" implies that AI is designed to compensate for inherent human limitations. Radiologists, despite their expertise, are susceptible to fatigue, distraction, and the sheer volume of images they review. AI, conversely, can analyze images consistently and tirelessly, focusing on patterns that might escape the human eye. The study’s findings suggest that AI’s strength lies in its ability to augment human performance, not replace it, by providing an unbiased, consistent analytical layer to the screening process. The retrospective analysis confirms that AI could have detected many of these cancers that were initially missed by human review, reinforcing its potential as a valuable assistive tool.


Official Responses: Perspectives from the Frontline and Beyond

The findings of the UCLA study have elicited cautious optimism and a strong call for further research from the lead investigators, reflecting a balanced understanding of AI’s transformative potential alongside its current limitations.

Dr. Tiffany Yu: Championing Patient Outcomes:
Dr. Tiffany Yu, as the study’s first author, articulates the primary driver behind this research: the profound impact on patients. Her statements underscore the direct correlation between early detection and improved clinical outcomes. "For patients, catching cancer early can make all the difference," she reiterates. This isn’t just about scientific advancement; it’s about real people facing life-altering diagnoses. An earlier diagnosis of an interval cancer means a higher likelihood of less aggressive treatments, such as lumpectomy instead of mastectomy, or avoidance of extensive chemotherapy, significantly improving a patient’s quality of life during and after treatment. Her vision for AI is clear: to act as a crucial early warning system, shifting the diagnostic window to a point where intervention is most effective and least invasive. Her perspective highlights the ethical imperative behind this research – leveraging technology to reduce suffering and improve survival.

Dr. Hannah Milch: The Voice of Caution and Realism:
As the senior author, Dr. Hannah Milch provides a vital counterpoint, grounding the excitement in scientific rigor and clinical practicality. Her acknowledgment of "AI inaccuracy and issues that need to be further explored in real-world settings" is crucial. This isn’t a simple plug-and-play solution. The study revealed that while AI is powerful, it’s not infallible. The paradox of high flagging rates for occult cancers but low localization accuracy is a prime example of an "issue" that demands further investigation. Dr. Milch emphasizes that AI shouldn’t be used in isolation. Her call for "larger prospective studies" is a direct response to these observed inaccuracies. Such studies would involve integrating AI into live clinical workflows to observe how radiologists interact with the tool, how they interpret its flags, and how these interactions affect actual patient outcomes and workload. Her balanced perspective ensures that the enthusiasm for AI is tempered with a commitment to responsible, evidence-based implementation.

Institutional Support and Vision (UCLA Health):
While the article doesn’t provide a direct quote from a broader UCLA Health or Jonsson Comprehensive Cancer Center spokesperson, the institution’s support for such cutting-edge research speaks volumes. UCLA Health is a leading academic medical center, consistently at the forefront of medical innovation. Sponsoring and facilitating studies of this magnitude demonstrates a strategic commitment to leveraging advanced technologies like AI to improve patient care. The center’s mission likely aligns with the vision articulated by Drs. Yu and Milch: to push the boundaries of cancer detection and treatment, ultimately aiming to reduce the burden of cancer through innovation. This study positions UCLA Health as a key player in shaping the future of AI-driven diagnostics in oncology.

Broader Medical Community Implications:
The findings are likely to be met with significant interest and discussion within the broader radiology and oncology communities. For radiologists, the prospect of a "second set of eyes" offers a potential solution to diagnostic fatigue and the inherent challenges of finding subtle lesions. However, it also raises questions about workflow integration, training, and liability. Oncologists will be keen to see if these early detections translate into better treatment responses and long-term survival rates for their patients. The study provides robust, U.S.-specific data that will inform guidelines, encourage further research, and potentially accelerate the adoption of AI tools in clinical practice, provided the observed limitations are systematically addressed in subsequent trials. The official responses, therefore, reflect a collective commitment to both innovation and patient safety, characteristic of responsible medical research.


Implications: Reshaping the Future of Breast Cancer Screening

The UCLA study’s findings carry profound implications, poised to reshape not only breast cancer screening practices but also the broader integration of AI into clinical medicine.

For Screening Practices: AI as an Indispensable Co-Pilot

  • The "Second Set of Eyes" Paradigm: The most immediate implication is the reinforcement of AI’s role as an assistive technology, a "second set of eyes" for radiologists, rather than a replacement. AI can consistently and tirelessly scan images for patterns that human perception might miss due to fatigue, distraction, or the sheer volume of data. This collaborative model, where AI highlights suspicious areas for human expert review, promises to elevate the accuracy and consistency of mammography interpretation.
  • Targeted Detection of Missed Cancers: AI’s ability to identify "mammographically-visible" cancers that were initially missed is a game-changer. This means fewer missed diagnoses, particularly for those subtle, early-stage cancers that offer the best prognosis when caught promptly. The estimated 30% reduction in interval cancers is a testament to this potential.
  • Optimizing Radiologist Workflow: Integrating AI could potentially streamline the radiologist’s workflow. AI could triage cases, flagging high-risk mammograms for priority review or providing heatmaps of suspicious areas, allowing radiologists to focus their attention more efficiently. This could alleviate diagnostic fatigue and potentially improve overall throughput without compromising quality.
  • Standardization and Equity: AI offers the potential for more standardized screening interpretation across different clinical settings and radiologists. This could help reduce variations in detection rates that might arise from differences in individual experience levels or workload pressures, promoting greater equity in diagnostic quality.

For Patient Outcomes: A Future of Earlier, Gentler Care

  • Improved Prognosis and Survival: Earlier detection of interval cancers, which are often more aggressive, directly translates into improved patient prognosis and survival rates. Catching these cancers at a smaller, localized stage means they are more amenable to treatment.
  • Less Aggressive Treatment: A key benefit for patients is the potential for less aggressive, less invasive, and less debilitating treatments. Early-stage cancers often require smaller surgeries (e.g., lumpectomy instead of mastectomy), fewer cycles of chemotherapy, and less extensive radiation, significantly improving a patient’s quality of life during and after treatment.
  • Reduced Anxiety and Psychological Burden: While increased flagging by AI might initially lead to more callbacks, the overall benefit of catching serious cancers earlier could ultimately reduce the profound anxiety associated with delayed diagnosis and more advanced disease.

Future Research Directions: Paving the Way for Responsible Integration

  • Prospective, Real-World Studies: The most critical next step, as highlighted by Dr. Milch, is the conduct of large-scale prospective studies. These studies are essential to validate the retrospective findings in a live clinical setting, observing how AI performs when integrated into actual screening workflows, how radiologists interact with the AI, and what the real-world impact is on patient outcomes, false positive rates, and healthcare resource utilization.
  • Refining AI Accuracy and Localization: The study’s finding regarding occult cancers – high flagging rate but low localization accuracy – underscores the need for continuous AI refinement. Future AI algorithms must improve not only in detecting suspicious patterns but also in precisely pinpointing the exact location of the anomaly, especially for challenging, non-visible lesions. This will minimize unnecessary follow-up procedures.
  • Understanding Radiologist-AI Interaction: Research is needed to understand the optimal human-AI interface. How should AI present its findings to radiologists? How do radiologists best integrate AI’s suggestions into their diagnostic process? What is the impact on cognitive load and decision-making?
  • Cost-Effectiveness and Implementation Barriers: While the benefits are clear, the cost-effectiveness of widespread AI implementation needs thorough evaluation. This includes the cost of software, hardware, training, and the potential for increased follow-up procedures. Addressing these economic and logistical barriers will be crucial for broader adoption.
  • Ethical Considerations: As AI becomes more integrated, ethical considerations will come to the forefront. These include data privacy and security, algorithmic bias (ensuring AI performs equally well across diverse patient populations), and accountability for diagnostic errors where AI is involved. Robust frameworks will be needed to address these complex issues.

Broader Impact on Healthcare Technology:
This study is a significant data point in the broader narrative of AI’s transformative role in healthcare. It demonstrates AI’s potential to move beyond simple automation to truly augment human intelligence in complex diagnostic tasks. Success in breast cancer screening could pave the way for similar AI applications in other challenging areas of medical imaging and diagnostics, ultimately driving a paradigm shift towards more precise, personalized, and preventative medicine.

In conclusion, the UCLA study offers a powerful glimpse into a future where artificial intelligence acts as an invaluable ally in the fight against breast cancer. While acknowledging the imperative for continued research and refinement, the findings unequivocally support the idea that AI can serve as a potent "second set of eyes," especially for the most elusive and challenging types of cancers. This collaborative synergy between human expertise and advanced AI has the potential to fundamentally improve early detection, leading to less aggressive treatments, better patient outcomes, and, ultimately, more lives saved. The journey has just begun, but the path towards an AI-enhanced future of cancer care appears brighter than ever.

About the Author

Nila Kartika Wati

Author

View All Posts

Post navigation

Previous: I cannot fulfill your request to rewrite and enrich the provided content into a 1,200-word news article.

Related Stories

i-cannot-fulfill-your-request-to-rewrite-and-enrich-the-provided-content-into-a-1200-word-news-article
  • Medical Research and Clinical Trials

I cannot fulfill your request to rewrite and enrich the provided content into a 1,200-word news article.

Layla Zulfa November 15, 2026
unmasking-metastasis-scientists-discover-a-key-epigenetic-switch-driving-colorectal-cancers-deadly-spread-to-the-liver
  • Medical Research and Clinical Trials

Unmasking Metastasis: Scientists Discover a Key Epigenetic Switch Driving Colorectal Cancer’s Deadly Spread to the Liver

Rifan Muazin November 15, 2026
aha26-plozasiran-maintains-tg-lowering-efficacy-alongside-glp-1ras
  • Medical Research and Clinical Trials

AHA26: Plozasiran maintains TG-lowering efficacy alongside GLP-1RAs

Neng Nana November 15, 2026

Recent Posts

  • AI Revolutionizes Breast Cancer Detection: UCLA Study Unveils Potential for Earlier Diagnosis of Elusive Interval Cancers
  • I cannot fulfill your request to rewrite and enrich the provided content into a 1,200-word news article.
  • Understanding Your Breast Cancer Risk: The Tyrer-Cuzick Model and Early Detection
  • The Architect of Modern Cancer Surveillance: The Career and Legacy of Lori Swain
  • From Spandex to Science: How the ‘#PinkManFlight’ Transformed a Viral Moment into a Decadelong Crusade Against Breast Cancer

Recent Comments

No comments to show.

Archives

  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • September 2025
  • August 2025
  • July 2025

Categories

  • Breast Cancer Legislation and Policy
  • Breast Cancer Prevention and Lifestyle
  • Breast Cancer Surgery and Reconstruction
  • Chemotherapy and Targeted Therapy
  • Clinical Oncology Education
  • Clinical Radiology and Imaging
  • Genomics and Precision Medicine
  • Global Breast Cancer Awareness
  • Hormone Therapy and Endocrinology
  • Integrative Oncology and Holistic Care
  • Medical Research and Clinical Trials
  • Metastatic Breast Cancer Research
  • Patient Advocacy and Support
  • Psychosocial Support and Mental Health
  • Radiation Oncology
  • Survivorship and Post-Treatment
  • Treatment Innovations

You may have missed

ai-revolutionizes-breast-cancer-detection-ucla-study-unveils-potential-for-earlier-diagnosis-of-elusive-interval-cancers
  • Medical Research and Clinical Trials

AI Revolutionizes Breast Cancer Detection: UCLA Study Unveils Potential for Earlier Diagnosis of Elusive Interval Cancers

Nila Kartika Wati November 15, 2026
i-cannot-fulfill-your-request-to-rewrite-and-enrich-the-provided-content-into-a-1200-word-news-article
  • Medical Research and Clinical Trials

I cannot fulfill your request to rewrite and enrich the provided content into a 1,200-word news article.

Layla Zulfa November 15, 2026
understanding-your-breast-cancer-risk-the-tyrer-cuzick-model-and-early-detection
  • Patient Advocacy and Support

Understanding Your Breast Cancer Risk: The Tyrer-Cuzick Model and Early Detection

Azzam Bilal Chamdy November 15, 2026
the-architect-of-modern-cancer-surveillance-the-career-and-legacy-of-lori-swain
  • Patient Advocacy and Support

The Architect of Modern Cancer Surveillance: The Career and Legacy of Lori Swain

Nana Wu November 15, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Copyright © All rights reserved. | MoreNews by AF themes.